SCHEMBL14637697

SCHEMBL14637697

C[C@]1(N)CCCN(c2ccc(C(F)(F)F)cc2)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.40
TSHR P16473 2/20 0.40
HIF1A Q16665 2/20 0.40
USP2 O75604 2/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CA12 O43570 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
FPR1 P21462 1/20 0.39
FPR2 P25090 1/20 0.39
PTGES O14684 2/20 0.38
DHFR P00374 1/20 0.38
HSD11B1 P28845 1/20 0.38
AKR1C3 P42330 1/20 0.38
NOTUM Q6P988 1/20 0.38
SLC6A9 P48067 1/20 0.37
MLYCD O95822 1/20 0.36
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14638114 1.00 CYP3A4 (0.40) CYP3A4TSHRHIF1AUSP2CYP2D6
SCHEMBL15115344 0.84 CYP3A4 (0.44) CYP3A4TSHRHIF1AUSP2CYP2D6
SCHEMBL14650493 0.77 ROCK2 (0.38) CYP3A4CYP2D6ROCK2ROCK1CDC42BPA
SCHEMBL14637740 0.76 FPR1 (0.37) CYP3A4TSHRHIF1AUSP2CYP2D6
SCHEMBL14637736 0.76 FPR1 (0.37) CYP3A4TSHRHIF1AUSP2CYP2D6
SCHEMBL14636949 0.75 MAPT (0.59)
SCHEMBL14637993 0.75 MAPT (0.59)
SCHEMBL14637784 0.74 CYP3A4 (0.44) CYP3A4TSHRHIF1AUSP2CYP2D6
SCHEMBL28842325 0.74 CA12 (0.56) CYP3A4TSHRUSP2CA12CA2
SCHEMBL13285321 0.74 CA12 (0.56) CYP3A4TSHRUSP2CA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815909-B2 Diaminocyclohexane compounds and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815909-B2 Diaminocyclohexane compounds and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815909-B2 Diaminocyclohexane compounds and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-20130184284-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2013-07-18 US disclosed
US-20130184284-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2013-07-18 US disclosed
US-20130184284-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2013-07-18 US disclosed
WO-2013012827-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184284-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF NPY4R, NPY2R, NPY1R CYP3A4 1357/4885TSHR 245/4885HIF1A 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.